Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumors
The Pharma Data
JANUARY 18, 2021
IN FRANCE, FOUR CLINICAL CENTERS WILL ENROLL PATIENTS. “ The development of BT-001 is progressing well and we are pleased to start this clinical trial in France with patients being enrolled across the country in four reference clinical centers, and in other hospitals in Europe.
40 
Let's personalize your content